MOTS-c: A Research Overview of the Mitochondrial-Derived Peptide

MOTS-c is one of the more conceptually interesting peptides in current metabolic research, in part because of its origin. Most signaling peptides are encoded by genes in the cell nucleus. MOTS-c is not — it is encoded within the mitochondrial genome itself, which places it in a small and unusual class of molecules and helps explain the rapid growth of interest in it since its discovery.

This overview summarizes what the published literature reports about MOTS-c’s origin, its proposed mechanism, and the shape of its evidence base, which is substantial in animal models, early in humans, and absent at the level of completed clinical trials. Throughout, it describes what studies observed in their experimental systems. It is not dosing guidance, medical advice, or a claim about what the compound does in or for any person.

What MOTS-c Is

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16–amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene. It was first characterized by Lee and colleagues in a 2015 paper in Cell Metabolism, which identified it as a mitochondrial-derived peptide that regulates insulin sensitivity and metabolic homeostasis (Lee et al., 2015, Cell Metabolism). It belongs to a broader family of mitochondrial-derived peptides that also includes humanin.

The peptide is found in blood and in mitochondria-containing tissues, and a recurring observation across the literature is that circulating MOTS-c levels appear to decline with age — a correlation that has helped drive interest in the molecule among researchers studying metabolism and aging.

Proposed Mechanism

The mechanism described in the foundational work is indirect and somewhat elegant. In the 2015 study, MOTS-c was reported to inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to accumulation of AICAR and subsequent activation of AMPK — a central cellular energy sensor — with skeletal muscle appearing to be the primary target tissue (Lee et al., 2015, Cell Metabolism). Activating AMPK through this route, rather than through energy depletion, is part of why the peptide attracted attention.

A 2018 follow-up study added an unusual detail: under metabolic stress, MOTS-c translocated to the nucleus and influenced the expression of nuclear genes (Kim et al., 2018, Cell Metabolism). For a small peptide of mitochondrial origin to act as a regulator of nuclear gene expression is mechanistically notable, and it is one reason MOTS-c is often described as a signaling molecule rather than a simple metabolite.

The Evidence Base — and Its Boundaries

This is the most important section to read carefully, because MOTS-c’s evidence sits at three very different levels of strength, and conflating them is the most common error in popular write-ups.

Animal models (robust). In rodent studies, MOTS-c administration was reported to prevent diet-induced obesity and insulin resistance and to reverse age-dependent skeletal muscle insulin resistance (Lee et al., 2015). A 2021 study reported that MOTS-c treatment improved physical performance in mice across age groups (Reynolds et al., 2021, Nature Communications). These are consistent, replicated animal findings.

Human data (early, observational). The human evidence is mostly associative. Studies have reported that exercise raises MOTS-c levels in people — one widely cited finding observed muscle MOTS-c rising sharply after exercise, with a smaller increase in blood plasma (Reynolds et al., 2021) — and have correlated endogenous MOTS-c levels with insulin sensitivity in various populations. Associations are not the same as demonstrated treatment effects, and the human picture is, in places, mixed.

Clinical trials (absent). As of this writing, clinical trials of MOTS-c as a therapy have not been completed (MOTS-c exercise/metabolic evidence (Reynolds et al., Nat Commun 2021)). The molecule is biologically interesting, and the preclinical case is strong, but the human therapeutic case remains untested to the level required for an approved medicine.

Holding those three levels apart is the single most useful habit when reading about MOTS-c. Strong animal data, suggestive human associations, and no completed clinical trials are exactly where rigorous research begins — not where it concludes.

Regulatory and Anti-Doping Status

MOTS-c is not approved by the FDA for use in humans; it is described by regulatory and anti-doping authorities as an experimental peptide (USADA overview). It is not a legitimate dietary ingredient and cannot lawfully be used in dietary supplements.

There is an additional point that anyone in the athletic or fitness space should know. The U.S. Anti-Doping Agency has stated that athletes cannot obtain a therapeutic use exemption for MOTS-c, because there is no approved therapeutic use for it (USADA). Given that much of the popular interest in MOTS-c centers on exercise and performance, this status is not a footnote — it is the central context, and it is the kind of fact a careful reader should weigh directly.

Why MOTS-c Keeps Drawing Research Interest

The appeal is easy to see. MOTS-c is a naturally occurring, mitochondrially encoded peptide that sits close to the biological roots of metabolism and aging, with a well-characterized AMPK-linked mechanism, an unusual nuclear-signaling behavior, and a strong preclinical record. For researchers working in mitochondrial physiology, metabolic signaling, or longevity biology, it is a compound worth following — precisely because the mechanistic story is rich and the human story is still being written.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related mitochondrial-peptide and metabolic-signaling topics are collected in our peptide research library, which gathers reference material on the wider class of compounds discussed here.